Sponsored by Market IQ Media Group* | TODAY'S TOP ALERT! | Oncolytics Biotech (Nasdaq: ONCY) | | Hey folks, I hope you're having a great afternoon. | You should be if you managed to catch the "tactical trade" idea I released before the bell this morning… | I wrote about a clinical-stage biotech company that had begun a sharp reversal into the close on Friday. | I thought there was "a great chance" the stock could extend the rally today, and that "I would especially look for it to cross above $.90, and possibly even retest the $1 mark if things get really spicy. 🌶️" | As expected, Oncolytics Biotech Inc. (ONCY) is on the move, and as of this writing, it just crossed that $.90 mark: | | The reversal is being powered by a press release the company put out this morning that reads almost like a shareholder letter… | | It's worth reading in its entirety for a great idea of where the company stands. Here are some highlights: | The company said it "expects additional data readouts across our clinical development program in 2025" which form what it believes "is a clear pathway to future commercialization opportunities." | Those will follow the already-released "robust efficacy results" from its BRACELET-1 breast cancer study. | "In addition," interim CEO Wayne Pisano said, "our gastrointestinal cancer program continues to impress, resulting in meaningful collaborations with well-respected experts in the field." | Based on their insights, "we believe pelareorep has the potential to become a transformational immunotherapy." | The press release also noted ONCY's collaboration with Roche, which will extend to a registration-enabling study of ONCY's lead candidate in metastatic pancreatic ductal adenocarcinoma (PDAC). | The company also pointed out that next month, it will be presenting data from its ongoing PDAC study at the ASCO GI Symposium. | And lastly, another potential catalyst next month will be ONCY's presentation at the Biotech Showcase at the Hilton San Francisco Union Square and that it will be "meeting investors in addition to current and potential partners during the week of the J.P. Morgan Healthcare Conference." | As you probably know, partnerships for clinical-stage biotechs like ONCY can be very valuable. | I thought ONCY had the potential to hit the $1.00 mark today even before I came across that press release, and its price action so far suggests that's very much in the cards. | Stay laser-focused on this stock as things heat up. 🔥 | To Your Success, | | Jeff Bishop | P.S. Make sure you join me and over 1000 traders in the Market Master's trading room today for live trading signals and education. You can access it at no cost right now. | | | Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull | | | *Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." | Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received thirty five thousand dollars (cash) from Market IQ Media Group for advertising Oncolytics Biotech Inc for a three-day marketing program starting on December 23, 2024 | Previously, we received twenty thousand dollars by ach bank transfer by Axe Communications for advertising Oncolytics Biotech Inc for a one-day advertising program. This was paid by someone else not connected to Oncolytics Biotech Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. | Now, diving right into Oncolytics Biotech Inc might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, | Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep's with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
Tidak ada komentar:
Posting Komentar